Home / Cannabis Based Medicine

Cannabis Based Medicine

FDA Approves GW’s Cannabis-Based Drug Epidiolex for the Treatment of Rare, Severe Forms of Epilepsy

London, UK, Carlsbad, CA, June 25, 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration …

Read More »

Kalytera Provides Update on its Cannabis-Based Therapy for Prevention and Treatment of GVHD

SAN FRANCISCO and TEL AVIV, Israel, June 21, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the “Company” or “Kalytera”) today provided an update on its lead clinical development program evaluating cannabidiol (“CBD”) for the prevention and treatment of acute graft versus host disease (“GVHD”). GVHD is a …

Read More »

Most Oncologists Have Discussed Medical Marijuana with Patients

Data from a new survey show that as many as 80% of oncologists have discussed medical marijuana use with their patients. According to the authors, this is the first nationally-representative survey to examine oncologists’ practices and beliefs on the subject since the implementation of state medical marijuana laws. The research …

Read More »

GW Pharma Wins Unanimous Recommendation from FDA Committee for Approval of its Cannabis-Based Drug

London, UK, Carlsbad, CA, April 19, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Peripheral and Central Nervous System Drugs …

Read More »

GW Pharma Announces Publication of Landmark Epidiolex (cannabidiol) Study in The Lancet

London, UK, Carlsbad, CA, January 24, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The Lancet has published results from a Phase 3 …

Read More »

INSYS’ Cannabidiol Solution Receives FDA Fast Track Designation as Treatment for Prader-Willi Syndrome

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that …

Read More »

GW Pharma Reacquires Full Rights to Develop and Commercialize Sativex in the US

London, UK, 13 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex®(nabiximols) in the U.S. …

Read More »

Zynerba’s Cannabis-Based Drug Demonstrates Positive Results in Study in Fragile X Syndrome

DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive top line results from an open label exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol …

Read More »

Flex Pharma’s FLX-787 Granted FDA Fast Track Status for Treatment of Severe Muscle Cramps Associated with ALS

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for …

Read More »

Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs

TEL AVIV, Israel, June 30, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. These results greatly strengthen the company’s previously accumulated data on cannabinoid anti-tumor activity. …

Read More »